2.3. Data collection

Inclusion criteria for this analysis were the following: 1) histologically-confirmed thoracic malignancy, including lung cancer, mesothelioma, and thymic tumors, 2) with scheduled appointment for a consultation and/or administration of cancer treatment and/or hospitalized in the inpatient clinic, 3) from March 23^rd to April 17^th 2020 in the month following the publication of the clinical practice recommendations for the management of patients with thoracic malignancies in the context of the pandemia. This retrospective study was approved by the Institutional Data Review Committee of Institute Curie; all patients gave consent at the initiation of their care for the retrieving of healthcare information from their electronic medical record. Clinical data were then retrospectively collected, including patients baseline characteristics, histology, stage, treatment regimen, dates of treatment, and treatment modification, as well as COVID-19 status and death.